Grundläggande statistik
| CIK | 801748 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to HemaCare Corp.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-15223 HEMACARE CORPORATION (Exact name of registrant as specified in it |
|
| April 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-15223 HEMACARE CORPORATIO |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15223 CUSIP Number: 423498104 (Check one) x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended December 31, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| March 20, 2012 |
As filed with the Securities and Exchange Commission on March 20, 2012 Registration No. |
|
| January 13, 2012 |
WELLS FARGO REVOLVING LINE OF CREDIT NOTE $594,135.00 Beverly Hills, California December 1, 2011 Exhibit 10.2 WELLS FARGO REVOLVING LINE OF CREDIT NOTE $594,135.00 Beverly Hills, California December 1, 2011 FOR VALUE RECEIVED, the undersigned HemaCare Corporation and Coral Blood Services, Inc. (“Borrower”) promises to pay to the order of WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”) at its office at Beverly Hills RCBO, 433 N. Camden Drive, Suite 505, Beverly Hills, CA 90210, or at such othe |
|
| January 13, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 hema8k-010612.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 9, 2012 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other |
|
| January 13, 2012 |
THIRD AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT THIS AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of December 1, 2011, by and between HEMACARE CORPORATION, a California corporation and CORAL BLOOD SERVICES, INC., a California corporation (each individually a “Borrower”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”). Each reference herein to “Borrower” shall mean each |
|
| November 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): November 14, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or orga |
|
| November 18, 2011 |
HEMACARE REPORTS THIRD QUARTER RESULTS Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Pete van der Wal, Chief Executive Officer 877-310-0717 www.hemacare.com RELEASE DATE: November 14, 2011 HEMACARE REPORTS THIRD QUARTER RESULTS LOS ANGELES - HemaCare Corporation (OTCBB:HEMA) announced today that the Company generated 2011 third quarter revenue of $4.0 million from continuing operations and net i |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACAR |
|
| September 26, 2011 |
SC 13G 1 hema13g-tuuk.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 HemaCare Corporation (Name of Issuer) Common Stock, No Par Value (Title Class of Securities) 42349810 |
|
| September 26, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 HemaCare Corporation (Name of Issuer) Common Stock, No Par Value (Title Class of Securities) 423498104 (CUSIP Number) September 14, 2011 (Da |
|
| September 14, 2011 |
As filed with the Securities and Exchange Commission on September 13, 2011 Registration No. 333- As filed with the Securities and Exchange Commission on September 13, 2011 Registration No. |
|
| September 14, 2011 |
HEMACARE CORPORATION AMENDED AND RESTATED 2004 STOCK PURCHASE PLAN (Effective August 19, 2011) Exhibit 10.1 HEMACARE CORPORATION AMENDED AND RESTATED 2004 STOCK PURCHASE PLAN (Effective August 19, 2011) 1. Purpose of the Plan. The purpose of this Amended and Restated HemaCare Corporation 2004 Stock Purchase Plan is to offer the Employees, Non-Employee Directors, and Consultants the opportunity to acquire a proprietary interest in the Company. The Plan allows the Service Providers to purchas |
|
| August 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0- |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE COR |
|
| August 22, 2011 |
Exhibit 99.2 HEMACARE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2011 Pro Forma As Reported Adjustment (B) Pro Forma Assets Current assets: Cash and cash equivalents $ 2,194,000 $ 2,475,000 $ 4,669,000 Restricted cash 660,000 660,000 Accounts receivable, net of allowance for doubtful accounts of $95,000 2,761,000 2,761,000 Product inventories and supplies |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 11, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incor |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15223 CUSIP Number: 423498104 (Check one) o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended June 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transitio |
|
| July 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 11, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organiza |
|
| July 15, 2011 |
`AGREEMENT BY AND BETWEEN THE AMERICAN NATIONAL RED CROSS, AND HEMACARE CORPORATION Exhibit 10.1 `AGREEMENT BY AND BETWEEN THE AMERICAN NATIONAL RED CROSS, AND HEMACARE CORPORATION This blood purchase agreement ("Agreement") is effective as of July 11, 2011 ("Effective Date"). The American National Red Cross ("Red Cross"), desires to purchase from HemaCare Corporation ("Vendor"), and Vendor desires to sell to the Red Cross, certain blood products as described in this Agreement an |
|
| July 15, 2011 |
Exhibit 2.1 EXECUTION COPY ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 11, 2011 (the “Effective Date”), by and between The American National Red Cross (“Red Cross”), HemaCare Corporation (“HemaCare”), and Coral Blood Services, Inc. (“Coral” and, together with HemaCare, each a “Seller” and collectively the “Sellers”). Red Cross and the Seller |
|
| July 15, 2011 |
Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Pete van der Wal, Chief Executive Officer 877-310-0717 www.hemacare.com RELEASE DATE: July 11, 2011 HEMACARE SELLS RED BLOOD CELL COLLECTION OPERATION ASSETS TO AND ENTERS INTO A MULTI-YEAR PLATELET SUPPLY AGREEMENT WITH THE AMERICAN RED CROSS LOS ANGELES - HemaCare Corporation (OTCBB:HEMA) announced today that |
|
| July 15, 2011 |
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On July 11, 2011, HemaCare Corporation (the “Company”) and its wholly-owned subsidiary, Coral Blood Services, Inc. (collectively, the “Sellers”), completed the sale of the Sellers’ red blood cell collection operation assets (the “Assets”) in California and Maine to The American National Red Cross (the “Buyer”) pursuant to the terms |
|
| July 8, 2011 |
SECOND MODIFICATION TO PROMISSORY NOTE Exhibit 10.2 SECOND MODIFICATION TO PROMISSORY NOTE THIS MODIFICATION TO PROMISSORY NOTE (this “Modification”) is entered into as of July 5, 2011, by and between HEMACARE CORPORATION and CORAL BLOOD SERVICES, INC. (“Borrower”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”). RECITALS WHEREAS, Borrower is currently indebted to Bank pursuant to the terms and conditions of that certain Revolving |
|
| July 8, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 5, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organizat |
|
| July 8, 2011 |
SECOND AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT THIS AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is entered into as of July 5, 2011, by and between HEMACARE CORPORATION, a California corporation and CORAL BLOOD SERVICES, INC., a California corporation (each individually a "Borrower"), and WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank"). Each reference herein to “Borrower” shall mean each an |
|
| June 15, 2011 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 8, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorp |
|
| June 15, 2011 |
[LETTERHEAD OF MARCUM STONEFIELD Accountants, Advisors] Exhibit 16.1 [LETTERHEAD OF MARCUM STONEFIELD Accountants, Advisors] June 15, 2011 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 We have read Item 4.01 included in the Form 8-K/A of Hemacare Corporation dated June 8, 2011 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm in such Form 8-K/A; we are not in a |
|
| June 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 8, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organizat |
|
| May 31, 2011 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): May 25, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organizat |
|
| May 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE CO |
|
| May 11, 2011 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of March 9, 2011 and effective August 11, 2010, is between HemaCare Corporation (“HemaCare” or the “Company”) and Lisa Bacerra (“Executive”). This Agreement supersedes all other previous agreements and/or writings pertaining to the subject matter hereof. 1. At-Will Employment. HemaCare hereby employs Executive |
|
| May 11, 2011 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of March 9, 2011 and effective August 11, 2010, is between HemaCare Corporation (“HemaCare” or the “Company”) and Anna Stock (“Executive”). This Agreement supersedes all other previous agreements and/or writings pertaining to the subject matter hereof. 1. At-Will Employment. HemaCare hereby employs Executive an |
|
| May 11, 2011 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of December 1, 2010, is between HemaCare Corporation (“HemaCare” or the “Company”) and Pete van der Wal (“Executive”). This Agreement supersedes all other previous agreements and/or writings pertaining to the subject matter hereof. 1. At-Will Employment. HemaCare hereby employs Executive and Executive hereby ac |
|
| April 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party Other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Prox |
|
| March 23, 2011 |
Exhibit 10.25 BLOOD DONOR CENTER MANAGEMENT COMMUNITY MOBILE BLOOD COLLECTIONS SERVICES AGREEMENT USC BLOOD DONOR CENTER USC University Hospital I. RECITALS A. Whereas, USC University Hospital (“Hospital”) operates a medical center located at 1500 San Pablo Street, Los Angeles, California 90033; B. Whereas, HemaCare Corporation (“HemaCare”) headquartered at 21101 Oxnard Street, Woodland Hills, Cal |
|
| March 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K HEMACARE CORPORATION Form 10-K For the fiscal year ended December 31, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2011 |
THIRD AMENDMENT TO SERVICES AGREEMENT Exhibit 10.32 THIRD AMENDMENT TO SERVICES AGREEMENT THIS THIRD AMENDMENT TO SERVICES AGREEMENT (the “Amendment”) is made and entered into as of the later of November 1, 2009, or the execution of the Agreement by both parties (the “Effective Date”) between, the University of Southern California, on behalf of its USC Norris Cancer Hospital (“Hospital”) and HemaCare Corporation, a California corporat |
|
| March 23, 2011 |
Exhibit 10.26 FIRST AMENDMENT TO THE BLOOD DONOR CENTER MANAGEMENT COMMUNITY MOBILE BLOOD COLLECTIONS SERVICES AGREEMENT This FIRST AMENDMENT is entered into by and between USC University Hospital, Inc., doing business as USC University Hospital (“Hospital”), a medical center located at 1500 San Pablo Street, Los Angeles, California 90033 and HemaCare Corporation (“HemaCare”), located at 21101 Oxn |
|
| March 23, 2011 |
LETTERHEAD HEMACARE CORPORATION THERAPEUTIC APHERESIS SERVICE AGREEMENT Exhibit 10.29 LETTERHEAD HEMACARE CORPORATION THERAPEUTIC APHERESIS SERVICE AGREEMENT This Agreement is entered into this 30 day of January 2003 (effective date), between HemaCare Corporation ("HemaCare") 21101 Oxnard Street, Woodland Hills, CA 91367, and Kenneth Norris Jr. Cancer Hospital ("Hospitals") located in Los Angeles, California. This Agreement shall continue, month-to-month, from the eff |
|
| March 23, 2011 |
1st AMENDMENT TO SERVICES AGREEMENT Exhibit 10.30 1st AMENDMENT TO SERVICES AGREEMENT THIS 1ST AMENDMENT TO SERVICES AGREEMENT (the “Amendment”) is made and entered into between Tenet Healthsystem Norris, Inc., a California corporation, doing business as USC/Kenneth Norris Jr. Cancer Hospital (“Hospital”) and HemaCare Corporation, a California corporation (“HemaCare”). RECITALS A. Hospital and HemaCare are parties to that certain Se |
|
| March 23, 2011 |
Exhibit 10.27 SECOND AMENDMENT TO THE BLOOD DONOR CENTER MANAGEMENT COMMUNITY MOBILE BLOOD COLLECTIONS SERVICES AGREEMENT This SECOND AMENDMENT is entered into by and between USC University Hospital, Inc., doing business as USC University Hospital (“Hospital”), a medical center located at 1500 San Pablo Street, Los Angeles, California 90033 and HemaCare Corporation (“HemaCare”), located at 15350 S |
|
| March 23, 2011 |
Exhibit 10.28 THIRD AMENDMENT TO THE BLOOD DONOR CENTER MANAGEMENT COMMUNITY MOBILE BLOOD COLLECTIONS SERVICES AGREEMENT This THIRD AMENDMENT (the “THIRD AMENDMENT”) is entered into as May 1, 2009 (the “Amendment Effective Date”) by and between University of Southern California, on behalf of USC University Hospital (“Hospital”), a medical center located at 1500 San Pablo Street, Los Angeles, Calif |
|
| March 23, 2011 |
SECOND AMENDED AND RESTATED SERVICES AGREEMENT Exhibit 10.31 SECOND AMENDED AND RESTATED SERVICES AGREEMENT THIS SECOND AMENDED AND RESTATED SERVICES AGREEMENT (the “Amendment”) is made and entered into as of the later of April 1, 2008, or the execution of the Agreement by both parties (the “Effective Date”) between, Tenet Healthsystem Norris, Inc., a California corporation, doing business as USC/Kenneth Norris Jr. Cancer Hospital (“Hospital”) |
|
| March 23, 2011 |
SOFTWARE LICENSE AND SUPPORT SERVICES Exhibit 10.33 SOFTWARE LICENSE AND SUPPORT SERVICES AGREEMENT THIS SOFTWARE LICENSE AND SUPPORT SERVICES AGREEMENT (the “Agreement”) is entered into as of February 14, 2011 (“Reference Date”) by and between HemaCare Corporation, ("Customer"), having offices located at 15350 Sherman Way, Suite 350, Van Nuys, CA 91406 USA and Haemonetics Corporation® d/b/a Haemonetics Software Solutions ("Vendor"), |
|
| March 21, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): March 9, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organiza |
|
| March 15, 2011 |
HEMACARE REPORTS FOURTH QUARTER AND YEAR END RESULTS Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Pete van der Wal, Chief Executive Officer 877-310-0717 www.hemacare.com RELEASE DATE: March 11, 2011 HEMACARE REPORTS FOURTH QUARTER AND YEAR END RESULTS LOS ANGELES - HemaCare Corporation (OTCBB:HEMA) announced today that the Company generated fourth quarter revenue of $7.0 million and a net loss of $197,000, o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| March 11, 2011 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lisa Bacerra, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Hemacare Corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) o |
|
| February 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): February 18, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or orga |
|
| February 14, 2011 |
John McIlvery Partner Direct Voice Direct Fax Mobile E-Mail 818.444.4502 818.444.6302 626.705.0758 [email protected] February 14, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HemaCare Corporation Form 10-K for the Fiscal Year Ended December 31, 2009 Filed on March 23, 2010 File No.: 000-1522 |
|
| January 21, 2011 |
Exhibit 10.6 January 15, 2011 Hemacare Corporation Coral Blood Services, Inc. 15350 Sherman Way Suite 350 Van Nuys, CA 91406 Dear Lisa Bacerra: Wells Fargo Bank, National Association ("Bank"), has made certain credit accommodations available to Hemacare Corporation, a California corporation, and Coral Blood Services, Inc., a California corporation (collectively, “Borrowers” and each, a “Borrower”) |
|
| January 21, 2011 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida corporation (the “Company”), and Joseph Mauro (“Executive”) (together, the “Parties”). INTRODUCTION WHEREAS, the shareholders of the Company and HemaCare Corporation, a California corporation (“HemaCare”) are en |
|
| January 21, 2011 |
Exhibit 10.3 May 8, 2006 Teragenix Corporation 5440 NW 33rd Avenue, Suite 108 Ft. Lauderdale, FL 33309 HemaCare Corporation 21101 Oxnard Street Woodland Hills, California 91367 Re: Agreement to Replace Promissory Note Dear Joe and Judi: Reference is made to the following: 1. Promissory Note in the principal amount of $450,000, dated November 11, 2005, issued by Teragenix Corporation (“Teragenix”) |
|
| January 21, 2011 |
ASSIGNMENT FOR THE BENEFIT OF CREDITORS Exhibit 10.4 ASSIGNMENT FOR THE BENEFIT OF CREDITORS THIS ASSIGNMENT, made this 4th day of December, 2007, between HemaCare Bioscience, Inc., a Florida corporation, with its principal place of business at 5440 NW 33rd Street, Suite 108, Fort Lauderdale, Florida, 33309, hereinafter "ASSIGNOR," and PHIL VON KAHLE, whose address is Michael Moecker & Associates, Inc., 6861 S.W. 196 Avenue, Suite 201-0 |
|
| January 21, 2011 |
SECURITY AGREEMENT: SPECIFIC RIGHTS TO PAYMENT Exhibit 10.8 SECURITY AGREEMENT: SPECIFIC RIGHTS TO PAYMENT 1. GRANT OF SECURITY INTEREST. For valuable consideration, the undersigned HemaCare Corporation, or any of them ("Debtor"), hereby grants and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank") a security interest in the following accounts, deposit accounts, chattel paper (whether electronic or tangible), instruments, promissory |
|
| January 21, 2011 |
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE Exhibit 10.5 SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE This Settlement Agreement and Mutual General Release ("Agreement") is entered as of August 26, 2008 between HEMACARE CORPORATION (“HemaCare”) on the one hand and JOSEPH MAURO (“Mauro”) and VALENTIN ADIA (“Adia”) on the other hand, with reference to the following: RECITALS WHEREAS, in or around August 2006, HemaCare on the one hand and Ma |
|
| January 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 15, 2011 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organ |
|
| January 21, 2011 |
FIRST MODIFICATION TO PROMISSORY NOTE Exhibit 10.7 FIRST MODIFICATION TO PROMISSORY NOTE This modification to PROMISSORY NOTE (this “Modification”) is entered into as of January 15, 2011, by and between HEMACARE CORPORATION and CORAL BLOOD SERVICES, INC. (“Borrower”), and Wells Fargo Bank, National Association (“Bank”). RECITALS WHEREAS, Borrower is currently indebted to Bank pursuant to the terms and conditions of that certain Revolv |
|
| January 21, 2011 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida corporation (the “Company”), and Valentin Adia (“Executive”) (together, the “Parties”). INTRODUCTION WHEREAS, the shareholders of the Company and HemaCare Corporation, a California corporation (“HemaCare”) are e |
|
| January 14, 2011 |
John McIlvery Partner Direct Voice Direct Fax Mobile E-Mail 818.444.4502 818.444.6302 626.705.0758 [email protected] January 14, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HemaCare Corporation Form 10-K for the Fiscal Year Ended December 31, 2009 Filed on March 23, 2010 File No.: 000-15223 |
|
| December 22, 2010 |
John J. McIlvery Partner Direct Voice 818.444.4502 Direct Fax 818.444.6302 Mobile E-Mail 626.705.0758 [email protected] December 22, 2010 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HemaCare Corporation Form 10-K for the Fiscal Year Ended December 31, 2009 Filed on March 23, 2010 File |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACAR |
|
| October 29, 2010 |
[Letterhead of Stonefield Josephson, Inc.] Exhibit 16.1 [Letterhead of Stonefield Josephson, Inc.] October 27, 2010 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 We have read Item 4.01 included in the Form 8-K/A of Hemacare Corporation dated October 27, 2010 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm in such Form 8-K/A; we are not in a positi |
|
| October 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): October 1, 2010 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of inc |
|
| October 7, 2010 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): October 1, 2010 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organi |
|
| October 7, 2010 |
[Letterhead of Stonefield Josephson, Inc.] Exhibit 16.1 [Letterhead of Stonefield Josephson, Inc.] October 7, 2010 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 We have read Item 4.01 included in the Form 8-K of Hemacare Corporation dated October 1, 2010 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to |
|
| August 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* HemaCare Corp (Name of Issuer) OTC BB (Title of Class of Securities) 423498104 (CUSIP Number) August 23, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| August 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE COR |
|
| August 6, 2010 |
HemaCare Reports Return to Profitablity in Second Quarter Exhibit 99.1 HemaCare Reports Return to Profitablity in Second Quarter LOS ANGELES-(BUSINESS WIRE)-August 2, 2010-HemaCare Corporation (OTCBB:HEMA) announced today profitable second quarter 2010 results with a 4% increase in revenue over the first quarter of the year, and $224,000 of net income, a significant improvement over the first quarter loss of $204,000. The first quarter loss included $184 |
|
| August 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 2, 2010 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA 0-15223 95-3850412 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 18, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEMACARE CORPORATION (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorporation or Organization) 95-3280412 (I.R.S. Employer Identification No.) 15350 Sherman Way, Suite 350 Van Nuys, California (Address of Pri |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): May 11, 2010 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organizat |
|
| May 14, 2010 |
HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN (As Amended and Restated through May 11, 2010) Exhibit 10.1 HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN (As Amended and Restated through May 11, 2010) 1. Purpose of the Plan. The purpose of this Plan is to encourage ownership in the Company by key personnel whose long-term service is considered essential to the Company’s continued progress and, thereby, encourage recipients to act in the stockholders’ interest and share in the Company’s su |
|
| May 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE CO |
|
| May 12, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 12, 2010 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-3850412 |
|
| May 12, 2010 |
HemaCare Reports First Quarter Results LOS ANGELES, CA - (Marketwire - May 12, 2010) - HemaCare Corporation (OTCBB: HEMA) announced today first quarter 2010 results, with revenue of $7. |
|
| April 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 HEMACARE CORPORATION - (Name of Issuer) COMMON STOCK, NO PAR VALUE - (Title of Class of Securities) 423498104 - (CUSIP Number) April 2, 2010 |
|
| March 31, 2010 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-15223 HEMACARE CORPORATIO |
|
| March 23, 2010 |
HemaCare Corporation Basic and Diluted Net Income per Share Exhibit 11 HemaCare Corporation Basic and Diluted Net Income per Share Years ended December 31, 2009 2008 BASIC Weighted average common shares used to compute basic earnings per share 10,008,000 9,533,000 Net income - continuing operations $ 905,000 $ 899,000 Basic net income per share - continuing operations $ 0. |
|
| March 23, 2010 |
Exhibit 21 Subsidiaries of Registrant Coral Blood Services, Inc. HemaBiologics, Inc. HemaCare BioScience, Inc. |
|
| March 17, 2010 |
Exhibit 10.2 February 26, 2010 John Doumitt 63 Flintlock Lane Bell Canyon, CA 91307 Re: Separation Agreement and Release Dear Mr. Doumitt: This confirms your voluntary resignation from your employment with HemaCare Corporation (“HemaCare” or the “Company”), effective February 26, 2010. The Company is agreeable to providing you Severance, in accordance with, and if you accept, the terms of this Agr |
|
| March 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2010 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I.R.S |
|
| March 17, 2010 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of March 2, 2010, is between HemaCare Corporation (“HemaCare” or the “Company”) and Pete van der Wal ("Executive "), as follows. This Agreement supersedes all other previous agreements and/or writings. 1. At-Will Employment. HemaCare hereby offers to employ Executive and Executive hereby accepts employment to r |
|
| March 17, 2010 |
Exhibit 10.3 March 15, 2010 Robert Chilton 30020 Torre Pines Place Agoura Hills, CA 91301 Re: Separation Agreement and Release Dear Mr. Chilton: This confirms your voluntary resignation from your employment with HemaCare Corporation (“HemaCare” or the “Company”), effective March 26, 2010. The Company is agreeable to providing you Severance, in accordance with, and if you accept, the terms of this |
|
| March 3, 2010 |
HEMACARE NAMES VAN DER WAL PRESIDENT AND CEO EX-99.1 2 ex99-1.htm Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717 www.hemacare.com RELEASE DATE: March 1, 2010 HEMACARE NAMES VAN DER WAL PRESIDENT AND CEO LOS ANGELES - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) today announced that its Board of Directors has name |
|
| March 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2010 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I. |
|
| February 26, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 26, 2010 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-328 |
|
| February 26, 2010 |
HemaCare Reports Ninth Consecutive Profitable Quarter LOS ANGELES, CA - (Marketwire - February 26, 2010) - HemaCare Corporation (OTCBB: HEMA) announced today fourth quarter and year end 2009 results, which showed an 8% improvement in 4th quarter 2009 net income before discontinued operations compared to the prior year. |
|
| February 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* HemaCare Corp (Name of Issuer) OTC BB (Title of Class of Securities) 423498104 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 1, 2010 |
sc13gza UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. Three)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 4234981045 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): December 9, 2009 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| December 15, 2009 |
Exhibit 10.8 SECURITY AGREEMENT: EQUIPMENT 1. GRANT OF SECURITY INTEREST. For valuable consideration, the undersigned HemaCare Corporation and Coral Blood Services, Inc., or any of them (“Debtor”), hereby grants and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”) a security interest in all goods, tools, machinery, furnishings, furniture and other equipment, now or at any time hereafte |
|
| December 15, 2009 |
THIRD PARTY SECURITY AGREEMENT: EQUIPMENT Exhibit 10.6 THIRD PARTY SECURITY AGREEMENT: EQUIPMENT 1. GRANT OF SECURITY INTEREST. In consideration of any credit or other financial accommodation heretofore, now or hereafter extended or made to HemaCare Corporation and Coral Blood Services, Inc. (“Borrowers”), or any of them, by WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”), and for other valuable consideration, as security for the payment |
|
| December 15, 2009 |
CONTINUING SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY Exhibit 10.5 CONTINUING SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY 1. GRANT OF SECURITY INTEREST. For valuable consideration, the undersigned HemaCare Corporation and Coral Blood Services, Inc., or any of them (“Debtor”), hereby grants and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”) a security interest in all accounts, deposit accounts, chattel paper (whether electronic o |
|
| December 15, 2009 |
THIRD PARTY SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY Exhibit 10.4 THIRD PARTY SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY 1. GRANT OF SECURITY INTEREST. In consideration of any credit or other financial accommodation heretofore, now or hereafter extended or made to HemaCare Corporation and Coral Blood Services, Inc. (“Borrowers”), or any of them, by WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”), and for other valuable consideration, as sec |
|
| December 15, 2009 |
THIRD PARTY SECURITY AGREEMENT: EQUIPMENT Exhibit 10.7 THIRD PARTY SECURITY AGREEMENT: EQUIPMENT 1. GRANT OF SECURITY INTEREST. In consideration of any credit or other financial accommodation heretofore, now or hereafter extended or made to HemaCare Corporation and Coral Blood Services, Inc. (“Borrowers”), or any of them, by WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”), and for other valuable consideration, as security for the payment |
|
| December 15, 2009 |
Exhibit 10.1 CREDIT AGREEMENT THIS CREDIT AGREEMENT (this “Agreement”) is entered into as of December 4, 2009, by and between HEMACARE CORPORATION, a California corporation and CORAL BLOOD SERVICES, INC., a California corporation (each individually, a “Borrower”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”). Each reference herein to “Borrower” shall mean each and every party, collectively |
|
| December 15, 2009 |
THIRD PARTY SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY Exhibit 10.3 THIRD PARTY SECURITY AGREEMENT: RIGHTS TO PAYMENT AND INVENTORY 1. GRANT OF SECURITY INTEREST. In consideration of any credit or other financial accommodation heretofore, now or hereafter extended or made to HemaCare Corporation and Coral Blood Services, Inc. (“Borrowers”), or any of them, by WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”), and for other valuable consideration, as sec |
|
| December 15, 2009 |
Exhibit 10.2 WELLS FARGO REVOLVING LINE OF CREDIT NOTE $5,000,000.00 Beverly Hills, California December 4, 2009 FOR VALUE RECEIVED, the undersigned HemaCare Corporation and Coral Blood Services, Inc. (“Borrower”) promises to pay to the order of WELLS FARGO BANK, NATIONAL ASSOCIATION (“Bank”) at its office at Beverly Hills RCBO, 433 N. Camden Drive, Suite 505, Beverly Hills, CA 90210, or at such ot |
|
| December 11, 2009 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness a |
|
| December 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.2)* HemaCare Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 423498104 (CUSIP Number) Steven B. Gerber, 15350 Sherman Way, Suite 350, Van Nuys, California, 91406, (818) 226-1968 (Name, Address and Telephone Number of P |
|
| December 11, 2009 |
Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitute and appoint Robert S. Chilton, Executive Vice President, Chief Financial Officer and Corporate Secretary of HemaCare Corporation, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of H |
|
| November 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 12, 2009 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 HemaCare Corporation Exhibit 11 Basic and Diluted Net Income per Share For the three months ended September 30, For the nine months ended September 30, 2009 2008 2009 2008 BASIC Weighted average common shares used to compute basic earnings per share 10,050,000 9,696,000 9,994,000 9,415,000 Net income—continuing operations $ 246,000 $ 455,000 $ 697,000 $ 708,000 Basic net income per share—continuing operations $ 0. |
|
| November 9, 2009 |
HemaCare Reports Eighth Consecutive Profitable Quarter LOS ANGELES, CA - (Marketwire - November 09, 2009) - HemaCare Corporation (OTCBB: HEMA) announced today third quarter 2009 results, which include a 168% increase in income from operations compared to the same quarter of 2008. |
|
| November 9, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 09, 2009 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-328 |
|
| August 13, 2009 |
Exhibit 3.4 SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIS SECOND AMENDMENT (the “Amendment”), dated August 13, 2009, is entered into by and between HEMACARE CORPORATION, a California corporation and CORAL BLOOD SERVICES, INC., a California corporation (jointly and severally, the “Company”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (as more fully defined in Paragraph 1 of this Amendment, |
|
| August 13, 2009 |
Exhibit 3.3 FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIS FIRST AMENDMENT (the “Amendment”), dated August 13, 2009, is entered into by and between HEMACARE CORPORATION, a California corporation and CORAL BLOOD SERVICES, INC., a California corporation (jointly and severally, the “Company”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (as more fully defined in Paragraph 1 of this Amendment, “ |
|
| August 13, 2009 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 HemaCare Corporation Exhibit 11 Basic and Diluted Net Income per Share For the three months ended June 30, For the six months ended June 30, 2009 2008 2009 2008 BASIC Weighted average common shares used to compute basic earnings per share 10,028,000 9,635,000 9,966,000 9,272,000 Net income—continuing operations $ 369,000 $ 165,000 $ 450,000 $ 252,000 Basic net income per share—continuing operations $ 0. |
|
| August 13, 2009 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE |
|
| August 10, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 10, 2009 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-32804 |
|
| August 10, 2009 |
HemaCare Reports Increase in Second Quarter Profit on Record Revenue LOS ANGELES, CA - (Marketwire - August 10, 2009) - HemaCare Corporation (OTCBB: HEMA) announced today second quarter 2009 results, which include a 5% increase in revenue compared to the same quarter of 2008. |
|
| June 2, 2009 |
2009 Annual Meeting May 27, 2009 Exhibit 99.1 2009 Annual Meeting May 27, 2009 1 Safe Harbor Provision This presentation contains “forward-looking statements” under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Statements herein that are not historical facts are forward- |
|
| June 2, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): May 27, 2009 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organizat |
|
| June 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 28, 2009 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-3280412 |
|
| June 1, 2009 |
HemaCare Board Re-Elected and Gerber Named Chairman LOS ANGELES, CA - (Marketwire - May 28, 2009) - HemaCare Corporation (OTCBB: HEMA) announced at its annual meeting of shareholders yesterday, all HemaCare Corporation board members were re-elected by shareholders. |
|
| May 13, 2009 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACAR |
|
| May 13, 2009 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 For the three months ended March 31, 2009 2008 BASIC Weighted average common shares used to compute basic earnings per share 9,904,000 8,909,000 Net income—continuing operations $ 81,000 $ 87,000 Basic net income per share—continuing operations $ 0. |
|
| May 8, 2009 |
HemaCare Reports Sixth Consecutive Profitable Quarter LOS ANGELES, CA - (Marketwire - May 07, 2009) - HemaCare Corporation (OTCBB: HEMA) announced today first quarter 2009 results, which include a $1. |
|
| May 8, 2009 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 07, 2009 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-3280412 |
|
| April 15, 2009 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 6, 2009 |
Exhibit 31.2.1 CERTIFICATION I, Robert S. Chilton, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| April 6, 2009 |
Exhibit 31.1.1 CERTIFICATION I, John Doumitt, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe |
|
| April 6, 2009 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEM |
|
| April 6, 2009 |
EXHIBIT 32.1.1 CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge, the Quarterly Report on Form 10-Q for the three months ended September 30, 2008 of HemaCare Corporation (the “C |
|
| March 31, 2009 |
March 31, 2009 Tia Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Health Care Services Securities and Exchange Commission Mail Stop 3561 Washington, D. |
|
| March 26, 2009 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 11 HemaCare Corporation Basic and Diluted Net (Loss) Income per Share Years ended December 31, 2008 2007 BASIC Weighted average common shares used to compute basic earnings per share 9,533,000 8,687,000 Net income (loss)—continuing operations $ 899,000 $ (1,828,000 ) Basic net income (loss) per share—continuing operations $ 0. |
|
| March 26, 2009 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 26, 2009 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 21 Subsidiaries of Registrant Coral Blood Services, Inc. HemaBiologics, Inc. HemaCare BioScience, Inc. QuickLinks Exhibit 21 Subsidiaries of Registrant |
|
| March 26, 2009 |
HEMACARE CORPORATION INDEMNIFICATION AGREEMENT Exhibit 10.43 HEMACARE CORPORATION INDEMNIFICATION AGREEMENT This Indemnification Agreement (the Agreement), dated as of March 24, 2009 is made and effective as of the date set forth in Section 14 of the Agreement, by and between HemaCare Corporation, a California corporation (the Corporation), and John Doumitt, a director and/or officer of the Corporation (the Indemnitee). RECITALS A. The Corpora |
|
| March 25, 2009 |
EXHIBIT 32.1.1 CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge, the Annual Report on Form 10-K/A for the year ended December 31, 2007 of HemaCare Corporation (the "Company") f |
|
| March 25, 2009 |
Exhibit 31.2.1 CERTIFICATION I, Robert S. Chilton, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| March 25, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-15223 H |
|
| March 25, 2009 |
CONSENT OF STONEFIELD JOSEPHSON, INC., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.1.1 CONSENT OF STONEFIELD JOSEPHSON, INC., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 pertaining to the 2006 Equity Incentive Plan (No. 333-135663), 2004 Stock Purchase Plan (No. 333-116405 and 333-153072) and 1996 Stock Incentive Plan (No. 333-132603, 333-18601 and 333-114013), of HemaCare Corpor |
|
| March 25, 2009 |
Exhibit 31.1.1 CERTIFICATION I, John Doumitt, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec |
|
| February 25, 2009 |
HemaCare Reports Record 4th Quarter and 2008 Revenues LOS ANGELES, CA - (Marketwire - February 24, 2009) - HemaCare Corporation (OTCBB: HEMA) announced today fourth quarter and year ended 2008 results, with the highest levels of quarterly and annual revenue in the Company's history. |
|
| February 25, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 24, 2009 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-328 |
|
| February 24, 2009 |
February 24, 2009 Tia Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Health Care Services Securities and Exchange Commission Mail Stop 3561 Washington, D. |
|
| February 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 HEMACARE CORPORATION - (Name of Issuer) COMMON STOCK, NO PAR VALUE - (Title of Class of Securities) 423498104 - (CUSIP Number) February 20, 2 |
|
| February 17, 2009 |
Filed by Bowne Pure Compliance OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| February 13, 2009 |
sc13gza UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. Two)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 4234981045 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 8, 2009 |
Exhibit 99.1 December 31, 2008 John Doumitt 63 Flintlock Lane Bell Canyon, CA 91307 Dear John: This employment letter agreement is an amendment and restatement of your offer letter, dated October 10, 2007, in which you were offered the position of Executive Vice President, General Manager – Transfusable Products at HemaCare Corporation, a position reporting directly to the Chief Executive Officer. |
|
| January 8, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): December 31, 2008 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or orga |
|
| January 8, 2009 |
HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN (As Amended and Restated through December 31, 2008) Exhibit 99.5 HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN (As Amended and Restated through December 31, 2008) 1. Purpose of the Plan. The purpose of this Plan is to encourage ownership in the Company by key personnel whose long-term service is considered essential to the Company’s continued progress and, thereby, encourage recipients to act in the stockholders’ interest and share in the Company |
|
| January 8, 2009 |
Exhibit 99.3 CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (this "Agreement") by and between HemaCare Corporation., a California corporation (the "Company") and John Doumitt (the "Executive"), is dated as of this 31th day of December, 2008. This Agreement amends and restates the Change of Control Agreement by and between the Company and the Executive, dated as o |
|
| January 8, 2009 |
Exhibit 99.4 CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (this "Agreement") by and between HemaCare Corporation., a California corporation (the "Company") and Robert Chilton (the "Executive"), is dated as of this 31th day of December, 2008. This Agreement amends and restates the Change of Control Agreement by and between the Company and the Executive, dated as |
|
| January 8, 2009 |
HEMACARE CORPORATION 1996 STOCK INCENTIVE PLAN (As Amended and Restated Through December 31, 2008) Exhibit 99.6 HEMACARE CORPORATION 1996 STOCK INCENTIVE PLAN (As Amended and Restated Through December 31, 2008) SECTION 1. Purposes. The purposes of the HemaCare Corporation 1996 Stock Incentive Plan (the “Plan”) are to (i) enable HemaCare Corporation (the “Company”) and Related Companies (as defined below) to attract, motivate and retain top-quality directors, officers, employees, consultants, ad |
|
| January 8, 2009 |
Exhibit 99.2 December 31, 2008 Robert Chilton 30020 Torrepines Place Agoura Hills, CA 91301 Dear Bob: This employment letter agreement is an amendment and restatement of your offer letter, dated October 2, 2003, in which you were offered the position of Chief Financial Officer at HemaCare Corporation, a position reporting directly to the Chief Executive Officer. Your offer letter of October 2, 200 |
|
| November 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 HemaCare Corporation Basic and Diluted Net Income (Loss) per Share Three Months Ended September 30, Nine Months Ended September 30, 2008 2007 2008 2007 BASIC Weighted average common shares used to compute basic earnings per share 9,696,000 8,794,000 9,415,000 8,588,000 Net income (loss)—continuing operations $ 455,000 $ (1,027,000 ) $ 708,000 (1,960,000 ) Basic net income (loss) per share—continuing operations $ 0. |
|
| November 10, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 10, 2008 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-32 |
|
| November 10, 2008 |
Sales Growth and Lower Costs Drive Operating Results HemaCare Reports Profitable Third Quarter Sales Growth and Lower Costs Drive Operating Results LOS ANGELES, CA - 11/10/2008 - HemaCare Corporation (OTCBB: HEMA) announced today third quarter 2008 results. |
|
| October 2, 2008 |
Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717 www.hemacare.com RELEASE DATE: October 1, 2008 HEMACARE ANNOUNCES NEW CEO AND DIRECTORS LOS ANGELES - - - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) today announced that John Doumitt, age 44, currently the Company’s Gene |
|
| October 2, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): October 1, 2008 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organi |
|
| September 19, 2008 |
Exhibit 31.2.1 CERTIFICATION I, Robert S. Chilton, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| September 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-15223 H |
|
| September 19, 2008 |
CONSENT OF STONEFIELD JOSEPHSON, INC., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.1.1 CONSENT OF STONEFIELD JOSEPHSON, INC., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 pertaining to the 2006 Equity Incentive Plan (No. 333-135663), 2004 Stock Purchase Plan (No. 333-116405 and 333-153872) and 1996 Stock Incentive Plan (No. 333-132603, 333-18601 and 333-114013), of HemaCare Corpor |
|
| September 19, 2008 |
Exhibit 31.1.1 CERTIFICATION I, Julian Steffenhagen, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of HemaCare Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| September 19, 2008 |
EXHIBIT 32.1.1 CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge, the Annual Report on Form 10-K/A for the year ended December 31, 2007 of HemaCare Corporation (the “Company”) f |
|
| September 18, 2008 |
Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Judi Irving, Chief Executive Officer, and Robert Chilton, Chief Financial Officer and Corporate Secretary, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/o |
|
| September 18, 2008 |
Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Judi Irving, Chief Executive Officer and Robert Chilton, Chief Financial Officer and Corporate Secretary, signing singly, as the undersigned’s true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or |
|
| September 18, 2008 |
Exhibit 99.B HEMACARE CORPORATION NON-QUALIFIED STOCK OPTION AGREEMENT [1996 STOCK INCENTIVE PLAN] (Non-Qualified Stock Option Agreement Form 96-2) Terry Van Der Tuuk Date Option Granted: March 17, 2005 Name of Optionee 11605 Manor No. Of Shares: 25,000 Address Leawood, KS 66211 Option No.: 106 City, State, Zip THIS AGREEMENT is made as of the date set forth above, between HEMACARE CORPORATION, a |
|
| September 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HemaCare Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 423498104 (CUSIP Number) Steven B. Gerber, 15350 Sherman Way, Suite 350, Van Nuys, California, 91406, (818) 226-1968 (Name, Address and Telephone Number of |
|
| September 18, 2008 |
Exhibit 99.A HEMACARE CORPORATION NON-QUALIFIED STOCK OPTION AGREEMENT [1996 STOCK INCENTIVE PLAN] (Non-Qualified Stock Option Agreement Form 96-2) Terry Van Der Tuuk Date Option Granted: May 9, 2003 Name of Optionee 11605 Manor No. Of Shares: 25,000 Address Leawood, KS 66211 Option No.: 90 City, State, Zip THIS AGREEMENT is made as of the date set forth above, between HEMACARE CORPORATION, a Cali |
|
| September 18, 2008 |
Exhibit 99.C HEMACARE CORPORATION NON-QUALIFIED STOCK OPTION AGREEMENT [1996 STOCK INCENTIVE PLAN] (Non-Qualified Stock Option Agreement Form 96-2) Terry Van Der Tuuk Date Option Granted: March 14, 2006 Name of Optionee 11605 Manor No. Of Shares: 25,000 Address Leawood, KS 66211 Option No.: 112 City, State, Zip THIS AGREEMENT is made as of the date set forth above, between HEMACARE CORPORATION, a |
|
| September 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* HemaCare Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 423498104 (CUSIP Number) Terry Van Der Tuuk, 15350 Sherman Way, Suite 350, Van Nuys, California, 91406, (818) 226-1968 (Name, Address and Telephone Number of P |
|
| September 18, 2008 |
HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Exhibit 99.E Option #13 HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, capitalized terms shall have the meaning set forth in the HemaCare Corporation 2006 Equity Incentive Plan (the “Plan”). 1. NOTICE OF STOCK OPTION GRANT You have been granted an option to purchase Common Stock, subject to the terms and conditions of the Plan and this Optio |
|
| September 18, 2008 |
HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Exhibit 99.D Option #1 HEMACARE CORPORATION 2006 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, capitalized terms shall have the meaning set forth in the HemaCare Corporation 2006 Equity Incentive Plan (the “Plan”). 1. NOTICE OF STOCK OPTION GRANT You have been granted an option to purchase Common Stock, subject to the terms and conditions of the Plan and this Option |
|
| September 16, 2008 |
September 16, 2008 Tia Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Health Care Services Securities and Exchange Commission Mail Stop 3561 Washington, D. |
|
| September 9, 2008 |
September 9, 2008 Tia Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Health Care Services Securities and Exchange Commission Mail Stop 3561 Washington, D. |
|
| September 5, 2008 |
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE Exhibit 99.1 SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE This Settlement Agreement and Mutual General Release ("Agreement") is entered as of August 26, 2008 between HEMACARE CORPORATION (“HemaCare”) on the one hand and JOSEPH MAURO (“Mauro”) and VALENTIN ADIA (“Adia”) on the other hand, with reference to the following: RECITALS WHEREAS, in or around August 2006, HemaCare on the one hand and Ma |
|
| September 5, 2008 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): August 29, 2008 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organi |
|
| August 19, 2008 |
As filed with the Securities and Exchange Commission on August 19, 2008 As filed with the Securities and Exchange Commission on August 19, 2008 Registration No. |
|
| August 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 HemaCare Corporation Basic and Diluted Net Income (Loss) per Share Three Months Ended June 30, Six Months Ended June 30, 2008 2007 2008 2007 BASIC Weighted average common shares used to compute basic earnings per share 9,635,000 8,673,000 9,272,000 8,354,000 Net income (loss)—continuing operations $ 165,000 $ (614,000 ) $ 252,000 $ (932,000 ) Basic net income (loss) per share—continuing operations $ 0. |
|
| August 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 13, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 13, 2008 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-3280 |
|
| August 13, 2008 |
Sales Growth and Income From Discontinued Operations Produce $841,000 Improvement in Net Income HemaCare Reports Profitable Second Quarter Sales Growth and Income From Discontinued Operations Produce $841,000 Improvement in Net Income LOS ANGELES, CA - 08/13/2008 - HemaCare Corporation (OTCBB: HEMA) announced today a substantial improvement in the second quarter of 2008 when compared to the same period of 2007. |
|
| July 21, 2008 |
July 20, 2008 Tia Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Health Care Services Securities and Exchange Commission Mail Stop 3561 Washington, D. |
|
| May 15, 2008 |
QuickLinks - Click here to rapidly navigate through this document EXHIBIT 11 BASIC Weighted average common shares used to compute basic earnings per share 8,909,000 8,785,000 Net income (loss)—continuing operations $ 87,000 $ (317,000 ) Basic net income (loss) per share—continuing operations $ 0. |
|
| May 15, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2008 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 12, 2008 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-3280412 |
|
| May 12, 2008 |
Sales Growth and Cost Savings Produce $404,000 Improvement in Net Income HemaCare Reports Profitable First Quarter Sales Growth and Cost Savings Produce $404,000 Improvement in Net Income LOS ANGELES, CA - 05/12/2008 - HemaCare Corporation (OTCBB: HEMA) announced today first quarter 2008 results. |
|
| April 18, 2008 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 21 Subsidiaries of Registrant Coral Blood Services, Inc. HemaBiologics, Inc. HemaCare BioScience, Inc. QuickLinks Exhibit 21 |
|
| April 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 10.35 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "Amendment") is executed as of August 17, 2006, by and between ECI SHERMAN PLAZA LLC, a Delaware limited liability company ("Landlord"), and HEMACARE CORPORATION., a California corporation ("Tenant"). Recitals A. Landlord and Tenant entered into a Lease Agree |
|
| April 14, 2008 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 10.36 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this "Amendment") is executed as of April 11, 2007, by and between ECI SHERMAN PLAZA LLC, a Delaware limited liability company ("Landlord"), and HEMACARE CORPORATION, a California corporation ("Tenant"). Recitals A. Landlord and Tenant entered into a Lease Agree |
|
| April 14, 2008 |
WELLS FARGO BUSINESS CREDIT CREDIT AND SECURITY AGREEMENT QuickLinks - Click here to rapidly navigate through this document Exhibit 10.39 WELLS FARGO BUSINESS CREDIT CREDIT AND SECURITY AGREEMENT THIS CREDIT AND SECURITY AGREEMENT (the "Agreement") is dated April 10, 2008, and is entered into between HemaCare Corporation, a California corporation, and Coral Blood Services, Inc., a California corporation (jointly and severally, the "Company"), and Wells F |
|
| April 14, 2008 |
HemaCare Corporation Basic and Diluted Net (Loss) Income per Share QuickLinks - Click here to rapidly navigate through this document Exhibit 11 HemaCare Corporation Basic and Diluted Net (Loss) Income per Share Years ended December 31, 2007 2006 BASIC Weighted average common shares used to compute basic earnings per share 8,687,000 8,265,000 Net (loss) income—continuing operations $ (1,828,000 ) $ 1,471,000 Basic net (loss) income per share—continuing operations $ (0. |
|
| April 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 27, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* HemaCare Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 423498104 (CUSIP Number) Steven B. Gerber, 15350 Sherman Way, Suite 350, Van Nuys, California, 91406, (818) 226-1968 (Name, Address and Telephone Number of Per |
|
| March 27, 2008 |
Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitute and appoint Robert S. Chilton, Executive Vice President, Chief Financial Officer and Corporate Secretary of HemaCare Corporation, as the undersigned's true and lawful attorney-in-fact to: (a) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of H |
|
| March 24, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): March 19, 2008 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organiz |
|
| March 24, 2008 |
Exhibit 99.1 AMENDMENT AND EXTENSION OF RIGHTS AGREEMENT DATED AS OF MARCH 3, 1998 BETWEEN HEMACARE CORPORATION AND COMPUTERSHARE TRUST COMPANY, N.A., AS RIGHTS AGENT This Amendment and Extension ("Amendment") to the Rights Agreement dated as of March 3, 1998 ("Rights Agreement") between HemaCare Corporation ("Company") and Computershare Trust Company, N.A., successor rights agent to U.S. Stock Tr |
|
| March 17, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): March 11, 2008 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organiz |
|
| March 17, 2008 |
HEMACARE CORPORATION INDEMNIFICATION AGREEMENT Exhibit 99.1 HEMACARE CORPORATION INDEMNIFICATION AGREEMENT This Indemnification Agreement (the Agreement), dated as of November 9, 2007 is made and effective as of the date set forth in Section 14 of the Agreement, by and between HemaCare Corporation, a California corporation (the Corporation), and Julian Steffenhagen, a director and/or officer of the Corporation (the Indemnitee). RECITALS A. The |
|
| March 4, 2008 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 03, 2008 (Date of earliest event reported) HemaCare Corporation (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 0-15223 (Commission File Number) 95-32804 |
|
| March 4, 2008 |
HemaCare Reports Profitable Fourth Quarter Results From Continuing Operations LOS ANGELES, CA - 03/03/2008 - HemaCare Corporation (OTCBB: HEMA) announced today fourth quarter and year ended December 31, 2007 results. |
|
| February 7, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 HEMACARE CORPORATION (Name of Issuer) COMMON STOCK, NO PAR VALUE (Title of Class of Securities) 423498104 (CUSIP Number) November 8, 2007 (Da |
|
| December 14, 2007 |
ASSIGNMENT FOR THE BENEFIT OF CREDITORS EX-99.1 2 v097143ex99-1.htm Exhibit 99.1 ASSIGNMENT FOR THE BENEFIT OF CREDITORS THIS ASSIGNMENT, made this 4th day of December, 2007, between HemaCare Bioscience, Inc., a Florida corporation, with its principal place of business at 5440 NW 33rd Street, Suite 108, Fort Lauderdale, Florida, 33309, hereinafter "ASSIGNOR," and PHIL VON KAHLE, whose address is Michael Moecker & Associates, Inc., 6861 |
|
| December 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): December 7, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organ |
|
| November 27, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 HEMACARE CORPORATION (Name of Issuer) COMMON STOCK, NO PAR VALUE (Title of Class of Securities) 423498104 (CUSIP Number) November 8, 2007 (Date of Event Which Re |
|
| November 16, 2007 |
HemaCare Corporation Net Income (Loss) per Common and Common Equivalent Share EXHIBIT 11 HemaCare Corporation Net Income (Loss) per Common and Common Equivalent Share Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 BASIC Weighted average common shares used to compute basic earnings per share 8,794,000 8,298,000 8,588,000 8,162,000 Net income (loss) $ (5,596,000 ) $ 448,000 $ (6,356,000 ) $ 893,000 Basic net income (loss) per share $ (0. |
|
| November 16, 2007 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE CORPORATION |
|
| November 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-15223 CUSIP No.: 423498104 (Check One): o Form 10-K oForm 20-F o Form 11-K x Form 10-Q o Form N-SAR oForm N-CSR For Period Ended: September 30, 2007 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report |
|
| November 14, 2007 |
HEMACARE REPORTS THIRD QUARTER LOSS Exhibit 99.1 NEWS RELEASE For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717 www.hemacare.com RELEASE DATE: November 12, 2007 HEMACARE REPORTS THIRD QUARTER LOSS LOS ANGELES - - - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) today announced that third quarter 2007 operations resulted in a net loss of $5,596 |
|
| November 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I. |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 423498104 (CUSIP Number) October 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 423498104 (CUSIP Number) October 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| November 7, 2007 |
EXHIBIT 99.5 SECURITY AGREEMENT This SECURITY AGREEMENT (this “Agreement”) is made as of August 29, 2006, by Teragenix Corporation, a Florida corporation (the "Debtor"), to and in favor of Joseph Mauro (the “Secured Party”). Recitals: A. In connection with the transactions contemplated by the Stock Purchase Agreement, dated as of August 29, 2006 (the “Stock Purchase Agreement”), by and among the D |
|
| November 7, 2007 |
EXHIBIT 99.3 NONCOMPETITION AGREEMENT This Noncompetition Agreement (the “Agreement”) is made as of August 29, 2006, by and among (a) HemaCare Corporation, a California corporation (“Buyer”), (b) Teragenix Corporation, a Florida corporation (the “Company”), and (c) Joseph Mauro, an individual resident of the state of Florida (the “Seller”), and the holder of 27,306, or seventy-six and nine-tenths |
|
| November 7, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): November 5, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or organ |
|
| November 7, 2007 |
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT EXHIBIT 99.1 EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT In consideration of my employment by Teragenix Corporation (the "Company") and the compensation I receive from the Company, I agree that: 1. Proprietary Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business. "Proprietary Information" is information (wheth |
|
| November 7, 2007 |
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT EXHIBIT 99.2 EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT In consideration of my employment by Teragenix Corporation (the "Company") and the compensation I receive from the Company, I agree that: 1. Proprietary Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business. "Proprietary Information" is information (wheth |
|
| November 7, 2007 |
EXHIBIT 99.4 NONCOMPETITION AGREEMENT This Noncompetition Agreement (the “Agreement”) is made as of August 29, 2006, by and among (a) HemaCare Corporation, a California corporation (“Buyer”), (b) Teragenix Corporation, a Florida corporation (the “Company”), and (c) Valentin Adia, an individual resident of the state of Florida (the “Seller”), and the holder of 8,200, or twenty-three and one-tenth p |
|
| November 7, 2007 |
EXHIBIT 99.6 SECURITY AGREEMENT This SECURITY AGREEMENT (this “Agreement”) is made as of August 29, 2006, by Teragenix Corporation, a Florida corporation (the "Debtor"), to and in favor of Valentin Adia (the “Secured Party”). Recitals: A. In connection with the transactions contemplated by the Stock Purchase Agreement, dated as of August 29, 2006 (the “Stock Purchase Agreement”), by and among the |
|
| October 25, 2007 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Hemacare Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 423498104 (CUSIP Number) October 19, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 17, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 19, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction of incorporation or org |
|
| August 15, 2007 |
Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717, extension 5312 www.hemacare.com HEMACARE REPORTS IMPROVEMENT IN SEQUENTIAL SECOND QUARTER OPERATING PERFORMANCE BEFORE NON-RECURRING EXPENSES Los Angeles, Calif., August 14, 2007 - HemaCare Corporation (OTC Bulleting Board: HEM |
|
| August 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I.R. |
|
| August 14, 2007 |
EXHIBIT 11 HemaCare Corporation Net Income (Loss) per Common and Common Equivalent Share Three Months Ended Six Months Ended June 30, June 30, 2007 2006 2007 2006 BASIC Weighted average common shares used to compute basic earnings per share 8,673,000 8,199,000 8,354,000 8,122,000 Net income (loss) $ (413,000 ) $ 360,000 $ (760,000 ) $ 445,000 Basic net income (loss) per share $ (0. |
|
| August 14, 2007 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15223 HEMACARE CORPORATION (Exac |
|
| July 10, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 423498104 (CUSIP Number) June 30, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| July 10, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HemaCare Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 423498104 (CUSIP Number) June 30, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| July 2, 2007 |
Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717 www.hemacare.com RELEASE DATE: June 29, 2007 INTERIM CEO ANNOUNCED LOS ANGELES - - - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) reported today that Judi Irving has resigned as President, CEO and Company Director to pursu |
|
| July 2, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I.R.S. |
|
| May 29, 2007 |
2007 Annual Meeting May 23, 2007 Safe Harbor Provision EX-99.1 2 ex99-1.htm Exhibit 99.1 2007 Annual Meeting May 23, 2007 Safe Harbor Provision This presentation contains “forward-looking statements” under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.) Statements herein that are not historical |
|
| May 29, 2007 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdiction (Commission File Number) (I.R.S. |
|
| May 17, 2007 |
1st Quarter 2007 Earnings Conference Call EX-99.2 4 ex99-2.htm Exhibit 99.2 1st Quarter 2007 Earnings Conference Call Bob Chilton: Thank you, Jennifer. My name is Bob Chilton, and I am the Executive Vice President and Chief Financial Officer for HemaCare Corporation. With me today is Judi Irving, HemaCare’s President and Chief Executive Officer. We both would like to welcome everyone to HemaCare’s first quarter 2007 earnings conference ca |
|
| May 17, 2007 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 N E W S R E L E A S E For Immediate Release Contact: HemaCare Corporation Robert S. Chilton, Executive Vice President and Chief Financial Officer 877-310-0717 www.hemacare.com RELEASE DATE: May 14, 2007 HEMACARE REPORTS FIRST QUARTER 2007 RESULTS LOS ANGELES - - - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) today reported first quarter 2007 results. Revenue |
|
| May 17, 2007 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 eps2498.htm HEMACARE CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2007 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 000-15223 95-3280412 (State or other jurisdi |
|
| May 15, 2007 |
HemaCare Corporation Net Income per Common and Common Equivalent Share EXHIBIT 11 HemaCare Corporation Net Income per Common and Common Equivalent Share Three Months Ended March 31, 2007 2006 BASIC Weighted average common shares used to compute basic earnings per share 8,496,000 8,196,000 Net (loss) income $ (347,000 ) $ 85,000 Basic net (loss) income per share -0. |
